BCAX — Bicara Therapeutics Inc. Common Stock stock price, charts and financials

QT89Bicara Therapeutics Inc. Common Stock

Latest market price

27.94

-0.12-0.43%

Overview Short InterestFilings

BCAXQT89Bicara Therapeutics Inc. Common Stock·NASDAQ

Overview Short InterestFilings

27.94-0.43%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

AUPH-2.33%$15.48 MESO+4.96%$16.73 ZBIO-1.46%$31.96 GHRS-2.07%$29.64 TSHA-0.69%$6.51 STOK-1.46%$32.23 ABCL+31.03%$9.08 VRDN-2.29%$23.05

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	36.33%	Shs Outstand	54.78M	Perf Week	3.54%

Market Cap	1.54B	Forward P/E	-	EPS next Y	-3.70	Insider Trans	11.30%	Shs Float	35.26M	Perf Month	-5.46%

Enterprise Value	1.22B	PEG	0.22	EPS next Q	-	Inst Own	-	Short Float	26.42%	Perf Quarter	21.52%

Income	-141.88M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	13.67	Perf Half Y	85.83%

Sales	0.00	P/B	3.31	EPS next Y	-6.17%	ROA	-28.42%	Short Interest	9.32M	Perf YTD	66.73%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-35.89%	52W High	30.86 -9.45%	Perf Year	168.77%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-33.77%	52W Low	9.53 193.21%	Perf 3Y	-

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	5.02% 5.08%	Perf 5Y	-

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-122.40%	Oper. Margin	0.00%	ATR (14)	1.46	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	13.85	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	56.94	Recom	2.29

Dividend Gr. 3/5Y	-	Current Ratio	13.85	EPS Q/Q	-36.76%	SMA20	2.97%	Beta	1.01	Target Price	32.33

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	10.02%	Rel Volume	0.80	Prev Close	28.06

Employees	103	LT Debt/Eq	0.00	Earnings	Aug 11	SMA200	39.31%	Avg Volume	711.93K	Price	27.94

IPO Date	Sep 13, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-43.23% -	Net Debt/EBITDA	2.05	Volume	570,567	Change	-0.43%

Analyst Ratings

Date	Action	Analyst	Rating	Target
May-12-26	Reiterated	Goldman Sachs	Neutral	$14 → $18
May-12-26	Reiterated	Morgan Stanley	Overweight	$35 → $37
May-11-26	Initiated	Guggenheim	Buy	$42
Feb-11-26	Reiterated	Goldman Sachs		$14
Jan-08-26	Initiated	BTIG	Buy	$28
Dec-17-25	Initiated	Mizuho	Neutral	$18
Aug-22-25	Reiterated	HC Wainwright & Co.	Buy	$40
May-23-25	Upgrade	Wells Fargo	Underweight → Equal Weight	$8.00
Mar-27-25	Reiterated	Stifel Nicolaus		$47 → $48
Oct-08-24	Initiated	Morgan Stanley	Overweight	$35

Latest News

Aug-04-26

Aug-04-2608:30AM

Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ETglobenewswire.com

Jul-31-26

Jul-31-2609:00PM

Top movers in Friday's after hours sessionChartMill

Jul-28-26

Jul-28-2608:30AM

Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directorsglobenewswire.com

Jul-02-26

Jul-02-2608:30AM

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

Company

Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors. At the forefront of their pipeline is ficerafusp alfa, a unique antibody designed to tackle solid cancers. This bifunctional therapeutic agent works by simultaneously engaging the epidermal growth factor receptor (EGFR) and binding to human transforming growth factor beta (TGF-b). Bicara Therapeutics operates as a subsidiary of Biocon Limited.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022
Total Revenue	0	0	0	—
Cost of Goods Sold Incl. D&A	0	0	0	—
Gross Profit	0	0	0	—
Selling, General and Administrative Excl. Other	31	19	9	—
Research and Development	125	64	31	—
Other Operating Expense	0	-1	0	—
Operating Income	-156	-82	-40	—
Interest Expense	0	0	0	—
Unusual Expense	—	—	—	—
Non-Operating Income (Expense)	18	15	-12	—
Net Income Before Taxes	-138	-68	-52	—
Income Taxes	0	0	0	—
Consolidated Net Income	-138	-68	-52	—
Net Income From Continuing Operations	-138	-68	-52	—
Net Income	-138	-68	-52	—
EPS (Recurring)	-2.52	-1.25	-1.00	—
EPS (Basic, Before Extraordinaries)	-2.52	-1.25	-1.00	—
EPS (Diluted)	-2.52	-1.25	-1.00	—
EBITDA	-138	-68	-52	—
Other After Tax Adjustments	—	—	—	—
Stock Option Compensation Expense	—	—	—	—
Price To Earnings Ratio	—	—	—	—
Price To Sales Ratio	—	—	—	—
Gross Margin	—	—	—	—
Operating Margin	—	—	—	—
Net Margin	—	—	—	—
Shares Outstanding	55	54	52	—
Market Capitalization	926	941	—	—
Operating Lease Expense	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mazumdar Claire	Chief Executive Officer	Jul 10 '26	Option Exercise	3.79	10,000	37,898	372,152	Jul 14
Mazumdar Claire	Chief Executive Officer	Jul 10 '26	Sale	28.42	10,000	284,198	362,152	Jul 14
Cohlhepp Ryan	President and COO	Jul 09 '26	Sale	29.00	536	15,544	181,641	Jul 10
Hyep Ivan	Chief Financial Officer	Jul 08 '26	Sale	28.85	28,000	807,672	129,855	Jul 10
Hyep Ivan	Chief Financial Officer	Jul 08 '26	Option Exercise	3.79	25,000	94,745	157,855	Jul 10
Cohlhepp Ryan	President and COO	Jul 08 '26	Option Exercise	3.79	18,750	71,059	210,391	Jul 10
Cohlhepp Ryan	President and COO	Jul 08 '26	Sale	28.98	28,214	817,586	182,177	Jul 10
Hyep Ivan	Chief Financial Officer	May 21 '26	Sale	20.42	9,200	187,883	145,355	May 26
Hyep Ivan	Chief Financial Officer	May 21 '26	Option Exercise	3.79	9,200	34,866	154,555	May 26
Mazumdar Claire	Chief Executive Officer	May 18 '26	Option Exercise	3.79	15,000	56,847	377,152	May 20
Mazumdar Claire	Chief Executive Officer	May 18 '26	Sale	20.04	15,000	300,579	362,152	May 20
Cohlhepp Ryan	President and COO	May 15 '26	Option Exercise	3.79	8,000	30,318	204,141	May 18
Cohlhepp Ryan	President and COO	May 15 '26	Sale	20.29	12,500	253,649	191,641	May 18
Raben David	Chief Medical Officer	Apr 27 '26	Option Exercise	3.79	5,500	20,844	60,786	Apr 28
Raben David	Chief Medical Officer	Apr 27 '26	Sale	22.88	5,500	125,830	55,286	Apr 28

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.